Economic impact of severe asthma in Spain: multicentre observational longitudinal study

References

• Plaza Moral V. Comité Ejecutivo de GEMA. [GEMA(4.0). Guidelines for asthma management]. Arch Bronconeumol 2015;51(Suppl 1):2–54.
   PubMedGoogle Scholar
• Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343–373.
   PubMed Web of Science ®Google Scholar
• Louis R. Severe asthma: how can we differentiate phenotypes? Swiss Med Wkly 2009;139:274–277.
   PubMed Web of Science ®Google Scholar
• Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J 2002;19:61–67.
   PubMed Web of Science ®Google Scholar
• Serra-Batlles J, Plaza V, Morejón E, Comella A, Brugués J. Costs of asthma according to the degree of severity. Eur Respir J 1998;12:1322–1326.
   PubMed Web of Science ®Google Scholar
• Martínez-Moragón E, Serra-Batllés J, De Diego A, Palop M, Casan P, Rubio-Terrés C, Pellicer C, et al. [Economic cost of treating the patient with asthma in Spain: the AsmaCost study]. Arch Bronconeumol 2009;45:481–486.
   PubMed Web of Science ®Google Scholar
• Doz M, Chouaid C, Com-Ruelle L, Calvo E, Brosa M, Robert J, Decuypère L, et al. The association between asthma control, health care costs, and quality of life in France and Spain. BMC Pulm Med 2013;13:15.
   PubMed Web of Science ®Google Scholar
• Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory Questionnaire. Am Rev Respir Dis 1992;145:1321–1327.
   PubMed Web of Science ®Google Scholar
• Juniper EF, Svensson K, Mörk A-C, Ståhl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005;99:553–558.
   PubMed Web of Science ®Google Scholar
• International Conference of Harmonization (ICH). ICH Tripartite Guideline for Good Clinical Practices E6 (R1), [Internet] June 10, 1996. Available from: http://apps.who.int/medicinedocs/documents/s22154en/s22154en.pdf [last accessed 1 Feb 2018].
   Google Scholar
• International Epidemiological Association-European Epidemiology Federation. Good epidemiological practice (GEP) IEA guidelines for proper conduct in epidemiologic research. [Internet] 2007. Available from: http://ieaweb.org/good-epidemiological-practice-gep/ [last accessed 1 Feb 2018].
   Google Scholar
• Cisneros Serrano C, Melero Moreno C, Almonacid Sánchez C, Perpiñá Tordera M, Picado Valles C, Martínez Moragón E, Pérez de Llano L, et al. Guidelines for severe uncontrolled asthma. Arch Bronconeumol 2015;51:235–246.
   PubMed Web of Science ®Google Scholar
• Olaguibel J, Quirce S, Juliá B, Fernández C, Fortuna A, Molina J, Plaza V, et al. Measurement of asthma control according to Global Initiative for Asthma guidelines: a comparison with the Asthma Control Questionnaire. Respir Res 2012;13:50.
   PubMed Web of Science ®Google Scholar
• Jefatura del Estado. [Spanish Royal Decree-Law 8/2010, May 20, whereby extraordinary measures are adopted to reduce the public deficit] [Internet]. Boletín Oficial Del Estado 2010. 45070–45128. Available from: https://www.boe.es/diario_boe/txt.php?id=BOE-A-2010-8228 [last accessed 17 Aug 2017].
   Google Scholar
• Gisbert R. Economy and health: economy, economic management and economic evaluation in the health field. Barcelona: Elsevier España – MASSON; 2002:296.
   Google Scholar
• Gisbert R, Brosa M. Healthcare cost database eSALUD [Internet]. Oblikue Consulting, SL. 2007. Available from: http://www.oblikue.com/en/index.htm [last accessed 1 Feb 2018].
   Google Scholar
• Consejo General de Colegios Oficiales de Farmacéuticos. Bot PLUS 2.0 [Internet] 2013. Available from: https://botplusweb.portalfarma.com [last accessed 16 May 2017].
   Google Scholar
• Instituto Nacional de Estadística [INE]. [Annual Survey of Salary Structure 2015] [Internet]. Available from: http://www.ine.es/ [last accessed 1 Feb 2018].
   Google Scholar
• Efron B, Tibshirani RJ. An introduction to the bootstrap. Boca Raton: Chapman & Hall/CRC; 1994:456.
   Google Scholar
• Efron B. Better bootstrap confidence intervals. J Am Stat Assoc 1987;82:171–185.
   Web of Science ®Google Scholar
• R Core Team. R: a language and environment for statistical computing vol. 739. Vienna, Austria: R Foundation for Statistical Computing; 2017.
   Google Scholar
• Ferrer M, Villasante C, Alonso J, Sobradillo V, Gabriel R, Vilagut G, Masa JF, et al. Interpretation of quality of life scores from the St George’s Respiratory Questionnaire. Eur Respir J 2002;19:405–413.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. GINA 2015 [Internet]. Available from: http://www.ginasthma.org/ [last accessed 1 Feb 2018].
   Google Scholar
• Cabrera-Navarro P. Anti-immunoglobulin E, a monoclonal antibody to treat respiratory disorders. Arch Bronconeumol 2006;42:241–245.
   PubMed Web of Science ®Google Scholar
• Dal Negro RW, Pradelli L, Tognella S, Micheletto C, Iannazzo S. Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy. Eur Ann Allergy Clin Immunol 2011;43:45–53.
   PubMedGoogle Scholar
• Dal Negro RW, Tognella S, Pradelli L. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy. J Asthma 2012;49:843–848.
   PubMed Web of Science ®Google Scholar
• Gutierrez Álvarez JF, Casas Maldonado F, García Polo C, Levy Naón A, Rodríguez Portal JA, Sojo González A, et al. [Supplement: update on treatment with omalizumab in bronchial asthma]. Rev Española Patol Torácica 2013;25:7–25.
   Google Scholar
• Quirce S, Bobolea I, Domínguez-Ortega J, Barranco P. Future biologic therapies in asthma. Arch Bronconeumol 2014;50:355–361.
   PubMed Web of Science ®Google Scholar
• Pérez de Llano LA, Villoro R, Merino M, Gómez Neira Mdel C, Muñiz C, Hidalgo Á. [Cost effectiveness of outpatient asthma clinics]. Arch Bronconeumol 2016;52:196–203.
   PubMed Web of Science ®Google Scholar
• Vennera MDC, Pérez De Llano L, Bardagí S, Ausin P, Sanjuas C, González H, Gullón JA, et al. Omalizumab therapy in severe asthma: experience from the Spanish registry-some new approaches. J Asthma 2012;49:416–422.
   PubMed Web of Science ®Google Scholar
• Levy AN, García a Ruiz AJ, García-Agua Soler N, Sanjuan MVH. Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective. J Asthma 2015;52:205–210.
   PubMed Web of Science ®Google Scholar
• Vennera Mdel C, Valero A, Uría E, Forné C, Picado C. Cost-effectiveness analysis of omalizumab for the treatment of severe persistent asthma in real clinical practice in Spain. Clin Drug Investig 2016;36:567–578.
   PubMed Web of Science ®Google Scholar
• Sicras-Mainar A, Huerta A, Saez M, Navarro-Artieda R. Caracterización de los pacientes con asma grave y estimación de los costes asociados: estudio retrospectivo de base poblacional. 50 Congreso Nacional Separ. 2017; Madrid, Spain.
   Google Scholar
• O’Neill S, Sweeney J, Patterson CC, Menzies-Gow A, Niven R, Mansur AH, Bucknall C, et al. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. Thorax 2015;70:376–378.
   PubMed Web of Science ®Google Scholar
• Kerkhof M, Tran TN, Soriano JB, Golam S, Gibson D, Hillyer EV, et al. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. Thorax. 2018;73:116–124.
   PubMed Web of Science ®Google Scholar
• Albers FC, Müllerová H, Gunsoy NB, Shin J-Y, Nelsen LM, Bradford ES, et al. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study. J Asthma. 2018;55:152–160.
   Google Scholar
• Ojeda P, de Burgoa VS. Costs associated with workdays lost and utilization of health care resources because of asthma in daily clinical practice in Spain. J Investig Allergol Clin Immunol 2013;23:234–241.
   PubMed Web of Science ®Google Scholar